Chemoradiation: An alernative to surgery for the curative treatment esophageal cancer?;Radiochimiothérapie (RCT): Une alternative curative à la chirurgie du cancer de l'œsophage?

Gastroenterologie Clinique et Biologique

Volumn 29, Issue 5, 2005, Pages 551-556

  Bedenne, Laurent ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PATIENT SELECTION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 20444490434     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(05)82127-X     Document Type: Short Survey

References (40)

1. Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-8.
2. Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius V, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997;15:277-84.
3. Coia LR, Minsky BD, Berkey BA, John MJ, Haller D, Landry J, et al. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Pattern of Care Study. J Clin Oncol 2000;18:455-62.
4. Smith TJ, Ryan LM, Douglass HO, Haller DG, Dayal Y, Kirkwood J, et al. Combined chemoradiotherapy vs radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 1998;42:269-76.
5. Wobbes T, Baron B, Paillot B, Jacob JH, Haegele P, Gignoux M, et al. Prospective randomised study of split-course radiotherapy versus cisplatin plus split-course radiotherapy in inoperable squamous cell carcinoma of the esophagus. Eur J Cancer 2001;37:470-7.
6. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (RTOG 94-05) phase III trial of combined-modality therapy for eosphageal cancer: high-dose vs standard-dose radiation therapy. J Clin Oncol 2002;20:1167-74.
7. Di Fiore F, Jacob J, Seng SH, Vié B, Roque I, Paillot B, et al. La durée de la chimiothérapie après radiochimiothé rapie concomitante modifie-t-elle l'évolution du cancer de l'œsophage non opéré? (résumé) Gastroenterol Clin Biol 2003;27:A53.
8. Bedenne L, Seitz JF, Milan C, Renard P, Conroy T, Lacourt J, et al. Cisplatine, 5-FU et radiothérapie préopératoire dans les cancers épidermoïdes de l'œsophage. Essai multicentrique de phase II FFCD 8804. Gastroenterol Clin Biol 1998;22:273-81.
9. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003;185:538-43.
10. Kaklamanos IG, Walker GR, Ferry C, Franceschi D, Livingstone AS. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 2003;10:754-61.
11. Mariette C, Plessen G, Triboulet JP. Influence de la radio- chimiothérapie néo-adjuvante sur la mortalité et la morbidité après oesophagectomie pour cancer (résumé) . Gastroenterol Clin Biol 2004;28:A101.
12. Ancona E, Ruol A, Santi S, Merigliano S, Chiarion Sileni V, Roussis H, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with respectable esophageal squamous cell carcinoma. Cancer 2001;91:2165-74.
13. Algan O, Coia LR, Keller SM, Engstrom PF, Weiner LM, Schultheiss TE, et al. Management of adenocarcinoma of the esophagus with chemoradiation alone or chemoradiation followed by esophagectomy: results of sequential non randomized phase II studies. Int J Radiat Oncol Biol Phys 1995;32:753-61.
14. Denham JW, Burmeister BH, Lamb DS, Spry NA, Joseph DJ, Hamilton CS, et al. Factors influencing outcome following radio-chemotherapy for esophageal cancer. The Trans Tasman Radiation Oncology Group (TROG). Radiother Oncol 1996;40:31-43.
15. Chan A, Wong A. Is combined chemotherapy and radiation therapy equally effective as surgical resection in localized esophageal carcinoma? Int J Radiat Oncol Biol Phys 1999;45:265-70.
16. Hironaka S, Ohtsu A, Boku N, Muto M, Nagashima F, Saito H, et al. Non randomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3) N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 2003;57:425-33.
17. Bedenne L, Michel P, Bouche O, Triboulet JP, Conroy T, Pezet M, et al. Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102) (résumé). Prog Proc Am Soc Clin Oncol 2002;21:130a.
18. Bonnetain F, Bedenne L, Michel P, et al. Definitive results of a comparative longitudinal quality of life study using the Spitzer QOL index in the randomized multicentric phase II trial FFCD 9102 (radiochemotherapy followed by surgery versus radiochemotherapy alone in patients with locally advanced esophageal cancer) (résumé). Prog Proc Am Soc Clin Oncol 2003;22:250.
19. Stahl M, Wilke H, Walz MK, Seeber S, Klump B, Budach W, et al. Randomized phase III trial in locally advanced squamous cell carcinoma of the esophagus: chemoradiation with and without surgery (résumé). Prog Proc Am Soc Clin Oncol 2003;22:250
20. Jacob JH, Seitz JF, Langlois C, Raoul JL, Bardet E, Bouché O, et al. Definitive concurrent chemo-radiation therapy in squamous cell carcinoma of the esophagus: preliminary results of a French randomized trial comparing standard versus split-course irradiation (FNCLCC-FFCD 9305) (ré sumé). Prog Proc Am Soc Clin Oncol 1999;18:270a.
21. Urba SG, Orringer MB, Ianettonni M, Hayman JA, Satoru H. Concurrent paclitaxel, cisplatin and radiotherapy as pre operative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98:2177-83.
22. Safran H, Gaissert H, Akerman P, Hesketh PJ, Chen M-H, Moore T, et al. Paclitaxel, cisplatin and concurrent radiation for esophageal cancer. Cancer Invest 2001;19:1-7.
23. Schnirer I, Komaki R, Yao JC, Swisher S, Putnam J, Pisters PWT, et al. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol 2001;24:91-5.
24. Adelstein DJ, Rice TW, Rybicki LA, Larto MA, Ciezki J, Saxton J, et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A non randomized comparison with fluorouracil-based therapy. J Clin Oncol 2000;19:2032-9.
25. Meluch A, Greco F, Gray JR, Thomas M, Sutton VM, Davis JL, et al. Preoperative therapy with concurrent paclitaxel, carboplatin, infusional 5 FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J 2003;9:251-60.
26. Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 2002;20:2844-50.
27. Swisher S, Ajani JA, Komaki R, Putnam J, Walsh G, Liao Z, et al. CPT11-taxotere-5FU regimen for induction and concurrent chemoradiotherapy in patients with respectable esophageal or GEJ carcinoma (résumé). Prog Proc Am Soc Clin Oncol 2003;22:272.
28. Swisher SG, Ajani JA, Komaki R, Nesbitt JC, Correa AM, Cox JD, et al. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy and surgery for locoregionally advanced esophageal cancer. Int J Radiation Oncology Biol Phys 2003;57:120-7.
29. Jones DR, Parker LA, Detterbeck FC, Egan TM. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 1999;85:1026-32.
30. Zuccaro G, Rice TW, Goldblum J, Medendorp SV, Becker M, Pimentel R, et al. Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer. Am J Gastroenterol 1999;94:906-12.
31. Laterza E, de Manzoni G, Guglielmi A, Rodella L, Tedesco P, Cordiano C. Endoscopic ultrasonography in the staging of esophageal carcinoma after preoperative radiotherapy and chemotherapy. Ann Thorac Surg 1999;67:1466-9.
32. Brucher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001;233:300-9.
33. Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, Gonen M, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003;21:428-32.
34. Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, et al. Positron emission tomography for assessment of the response to induction radiotherapy in locally advanced oesophageal cancer. Ann Oncol 2002;13:361-8.
35. Wieder H, Brücher B, Zimmerman F, Becker K, Lordick F, Beer A, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004;22:900-8.
36. Hironaka S, Hasebe T, Kamijo T, Ohtsu A, Boku N, Yoshida S, et al. Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy. Clin Cancer Res 2002;8:124-30.
37. Nakagawa S, Nishimaki T, Suzuki T, Kanda T, Kuwabara S, Hatakeyama K. Tumor angiogenesis as an independent prognostic factor after extended radical esophagectomy for invasive squamous cell carcinoma of the esophagus. Surgery 2001;129:302-8
38. Warnecke-Eberz U, Metzger R, Miyazono F, Baldus SE, Neiss S, Brabender J, et al. High specificity of quantitative excision repair cross-complementing 1 (ERCC1) messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 2004;10:3794-9.
39. Moreto M. Diagnosis of esophagogastric tumors. Endoscopy 2001;33:1-7.
40. Kishi K, Doki Y, Miyata H, Yano M, Yasuda T, Monden M. Prediction of the response to chemoradiation and prognosis in esophageal squamous cancer. Br J Surg 2002;89:597-603.